Making Digoxin Therapeutic Drug Monitoring More Effective
The DOI matches its Crossref record.
Abstract
Digoxin is an important drug in the treatment of patients with either congestive heart failure or atrial arrhythmia. Because of its narrow therapeutic range, digoxin serum concentrations are commonly monitored in both inpatients and outpatients. However, with the costs of health care skyrocketing, there is debate whether such therapeutic drug monitoring (TDM) is cost-effective. To reduce the number of samples drawn too soon after a previous dose and in an effort to improve digoxin TDM at this teaching hospital, a new dosing and monitoring policy was initiated. This policy involved uniform digoxin dosing at 5 p.m. (1700 h) for all inpatients and serum drug measurements at 7 a.m. (0700 h) the next day. By coordinating the time of dosing to be greater than 12 h prior to serum digoxin analysis, the number of inappropriate digoxin serum determinations have been reduced. This new protocol has increased the effectiveness of the toxicology laboratory and enhanced the efficiency of the house staff. Other issues concerning digoxin TDM are also addressed. These findings can be generalized to all drugs that are monitored at any hospital and can result in a significant cost savings and decrease the time spent analyzing inappropriate data.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“approximately 10% of patients excrete high levels of an inactive metabolite of digoxin, dihydrodigoxin, which results from the bacterial reduction of the α,β-unsaturated lactone ring61, 62”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [62]
Citations
Cites
Still being checked.
Cited by
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Microbiota–Host Transgenomic Metabolism, Bioactive Molecules from the Inside: Miniperspective
Turroni, S., Brigidi, P., Cavalli, A., & Candela, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00244 · Cited by 108
Evaluating the Appropriateness of Digoxin Level Monitoring
Cañas, F., Tanasijevic, M. J., Ma'luf, N., & Bates, D. W. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.4.363 · Cited by 51
Appropriateness of digoxin level monitoring
Mordasini, M., & Schlienger, R. (2002) · Swiss Medical Weekly · doi:10.4414/smw.2002.10064 · Cited by 32
Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring*
Takada, M., Goto, T., Kotake, T., Saito, M., Kawato, N., Nakai, M., Gunji, T., & Shibakawa, M. (2005) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2004.00612.x · Cited by 24
Metadata
- Authors
- Matzuk, M. M., Shlomchik, M., & Shaw, L. M.
- Affiliations
- Hospital of the University of Pennsylvania (US)
- Venue
- Therapeutic Drug Monitoring
- Published
- 1991-05
- Volume
- 13
- Issue
- 3
- Pages
- 215-219
- ISSN
- 0163-4356 (ISSN-L)
- OpenAlex
- W2039536404
- Cited by
- 17
- References
- 0
- Citations by year
- 2017: 2 · 2016: 1 · 2012: 2
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Therapeutic Drug Monitoring (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Health Sciences › Health Professions › General Health Professions › Healthcare cost, quality, practices
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- digoxin, serum drug concentration, cost-effectiveness, congestive heart failure, atrial arrhythmias, house staff
- MeSH terms
- Adult, Aged, Cost Control, Digoxin, Female, Humans, Male, Middle Aged, Monitoring, Physiologic, Drug Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Making Digoxin Therapeutic Drug Monitoring More Effective. https://app.cochat.ai/papers/10.1097/00007691-199105000-00005
- The paper
- Matzuk, M. M., Shlomchik, M., & Shaw, L. M. (1991). Making Digoxin Therapeutic Drug Monitoring More Effective. Therapeutic Drug Monitoring. https://doi.org/10.1097/00007691-199105000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.